Article Directory

Amgen NASDAQ: AMGN pharmaceutical company just released information stating positive performance results for Pivotal Postmenopausal Osteoporosis Trial for denosumab.

Study met primary endpoint of Reducing new vertebral fractures and secondary endpoints of decreasing time to first non-vertebral and hip fractures; adverse events similar to placebo. The past president of the National Osteoporosis Foundation Stated, " I am particularly excited about these findings because they indicate that denosumab may offer an important new option for patients."

Denosumab is the first fully human monoclonal antibody in late stage clinical development that particularly targets RANK Ligand, an important regulator of osteoclasts the cells that break down bone). Denosumab is being investigated for its potential to inhibit every stage of osteoclast activity by a targeted mechanism. Denosumab is being studied for a variety of bone loss conditions such as, rheumatoid arthritis, postmenopausal osteoporosis, and cancer treatment-induced bone loss in breast cancer and prostate cancer patients| in prostate cancer and breast cancer patients as well as for its potential to defer bone metastases and inhibit and treat bone destruction for many stages of cancer.

Osteoporosis is often referred to as the "silent epidemic", osteoporosis is a world wide problem illness that is increasing in dominance as the population of the world both ages and increases. WHO, The World Health Organization has just claimed osteoporosis as a significant health issue in addition to other major non-communicable diseases. We are dependent on the pharmaceutical companies to help combat this terrible disease.

Amgen states that the financial burden of osteoporosis is compared to as the "silent epidemi' to that of other major chronic diseases; for example, in the U.S. the costs associated with osteoporosis-related fractures are equivalent to those of cardiovascular disease and asthma (i)(ii)(iii). It has been reported that osteoporosis results in more hospital bed-days than stroke, myocardial infarction or breast cancer (iv).

Clinical pharmacist have been developing prescriptions drugs to help patient that have serious side effects. These products are created simultaneously the medications that aid in the treatment of the primary illness. The fact that data is available to help anticipate the potential side effects and interactions drugs have with one another is awesome.

There are several drugs that both, prevent and treat osteoporosis. A few prescriptions slow the rate of bone loss or increase bone thickness. Minute amounts of new bone growth can reduce the risk of breaking bones. It is important that you take vitamin D and calcium, exercise and eat well when you take osteoporosis prescriptions.